Amgen Inc.
Stocks
Constellation Energy Corporatio
Stocks
Amgen Inc. vs Constellation Energy: Which Stock Better Suits Healthcare or Utility Investors?
Last updated: June 5, 2026
Summary
Amgen Inc. and Constellation Energy are prominent U.S. stocks in the healthcare and utility sectors, respectively. While Amgen boasts higher revenue and a stronger profit margin, Constellation Energy offers a lower P/E ratio and a different dividend profile, making each suitable for distinct investment strategies based on sector focus and risk appetite.
Key Differences at a Glance
| Aspect | Amgen Inc. | Constellation Energy Corporatio | Winner |
|---|---|---|---|
| Market Capitalization | $186.52 billion | $94.49 billion | Amgen Inc. |
| P/E Ratio | 24.05 | 22.97 | Tie |
| Dividend Yield | 2.98% | 0.64% | Amgen Inc. |
| Beta (Volatility Measure) | 0.435 | 1.155 | Amgen Inc. |
| Revenue | $37.22 billion | $29.87 billion | Amgen Inc. |
Market Capitalization: Amgen's market cap nearly doubles Constellation Energy’s, indicating a larger, more established presence in the biotech sector with broader investor confidence.
P/E Ratio: Both stocks have similar P/E ratios, suggesting comparable valuation levels relative to earnings, though Amgen’s slightly higher ratio reflects higher growth expectations in biotech.
Dividend Yield: Amgen offers a significantly higher dividend yield, making it more attractive for income-focused investors seeking regular payouts.
Beta (Volatility Measure): Amgen’s low beta indicates stability and lower market volatility risk, ideal for conservative investors, whereas Constellation’s higher beta suggests greater price fluctuation.
Revenue: Amgen’s higher revenue underscores its larger scale in the biotech industry, which may translate to more stable earnings and better growth prospects.
Detailed Analysis
Amgen Inc., with a market capitalization of approximately $186.52 billion, surpasses Constellation Energy’s $94.49 billion, reflecting a more substantial market presence in the biotech sector. Its revenue of $37.22 billion is also notably higher than Constellation’s $29.87 billion, indicating stronger sales performance and larger operational scale. Amgen’s profit margin of roughly 21%, coupled with an EPS of 14.37, underscores its efficiency in converting revenues into profits, appealing to investors seeking growth with margin stability. Conversely, Constellation Energy, operating in the utilities sector, has a lower profit margin of around 12.7% and an EPS of 11.52, reflecting different sector dynamics but also a potentially steadier cash flow profile typical of utility companies.
Both stocks have similar P/E ratios—24.05 for Amgen and 22.97 for Constellation Energy—indicating their relative valuation levels are comparable, yet Amgen’s slightly higher ratio suggests higher growth expectations often associated with biotech firms. When considering risk and volatility, Amgen’s beta of 0.435 indicates it is considerably less volatile than the market, appealing to risk-averse investors prioritizing stability. In contrast, Constellation’s beta of 1.155 signals higher market sensitivity, which could be advantageous in bullish markets but risky during downturns.
Dividend yields are a critical factor for income investors, with Amgen offering nearly 3%, significantly higher than Constellation Energy’s 0.64%. This makes Amgen more suitable for those prioritizing dividend income. Despite the lower dividend, Constellation Energy’s larger forward P/E ratio of approximately 19.4 suggests potential growth in earnings that might justify its valuation. Both companies have experienced a 52-week high close to their current prices but remain within their respective ranges, reflecting stable market sentiment.
In summary, Amgen’s larger market cap, higher revenue, and dividend yield position it as a more attractive stock for growth and income-oriented investors within the healthcare sector. Meanwhile, Constellation Energy’s lower volatility and sector stability make it appealing for investors seeking diversified utilities exposure with moderate growth potential.
Verdict
Amgen Inc. emerges as the stronger choice for investors prioritizing growth, stability, and dividend income due to its larger market cap, higher revenue, and lower beta. However, Constellation Energy may appeal to those seeking exposure to the utility sector with slightly lower valuation risk and growth potential. Overall, for those focused on healthcare and biotech innovation, Amgen provides a more compelling investment profile.
Who Should Choose What
Choose Amgen Inc. if...
Best for growth-focused, income-seeking investors who want stability in the healthcare sector, especially those valuing higher dividend yields and lower volatility.
Choose Constellation Energy Corporatio if...
Best for investors looking for utility stocks with moderate growth prospects and higher sensitivity to market movements, suitable for diversified sector exposure.